Kathryn A Phillips

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look
    K A Phillips
    School of Pharmacy, University of California, San Francisco, USA
    AIDS 14:2159-69. 2000
  2. ncbi request reprint A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
    Kathryn A Phillips
    School of Pharmacy, Institute of Health Policy Studies and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California St, UCSF BOX 0613, San Francisco, CA 94143, USA
    Pharmacogenomics 5:1139-49. 2004
  3. ncbi request reprint Important step forward in HIV-testing technologies [correction of technolgies]
    Kathryn A Phillips
    UCSF School of Pharmacy, Institute for Health Policy Studies, University of California San Francisco, 3333 California Street, Box 0613, San Francisco, CA 94143, USA
    Am J Prev Med 25:167. 2003
  4. ncbi request reprint Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey
    Kathryn A Phillips
    sSchool of Pharmacy and Institute of Health Policy Studies, University of California San Francisco, 3333 California Street, Suite 420, Box 0613, San Francisco, CA 94143, USA
    Am J Prev Med 24:340-8. 2003
  5. ncbi request reprint An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California Street 420 Box 0613, San Francisco, CA 94143, USA
    Pharmacogenomics 4:231-9. 2003
  6. ncbi request reprint New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women
    Kathryn A Phillips
    University of California at San Francisco, San Francisco, California 94143, USA
    J Acquir Immune Defic Syndr 32:182-91. 2003
  7. ncbi request reprint Prescription drug dispensing limits and patterns
    Kathryn A Phillips
    Health Economics and Health Services Research, School of Pharmacy, Institute for Health Policy Studies, University of California, San Francisco 94143, USA
    Manag Care Interface 18:41-6. 2005
  8. ncbi request reprint Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs
    Kathryn A Phillips
    Program in Pharmacogenomics and Population Screening, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
    Am J Manag Care 10:425-32. 2004
  9. ncbi request reprint Health and economic benefits of increased beta-blocker use following myocardial infarction
    K A Phillips
    School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA
    JAMA 284:2748-54. 2000
  10. ncbi request reprint Impact of the U.S. panel on cost-effectiveness in health and medicine
    Kathryn A Phillips
    School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, CA 94143, USA
    Am J Prev Med 22:98-105. 2002

Detail Information

Publications56

  1. ncbi request reprint The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look
    K A Phillips
    School of Pharmacy, University of California, San Francisco, USA
    AIDS 14:2159-69. 2000
    ..To estimate the cost-effectiveness of approaches to expanded HIV counselling and testing...
  2. ncbi request reprint A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
    Kathryn A Phillips
    School of Pharmacy, Institute of Health Policy Studies and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California St, UCSF BOX 0613, San Francisco, CA 94143, USA
    Pharmacogenomics 5:1139-49. 2004
    ..Further analyses that can be used to guide the use of pharmacogenomics in clinical practice and in developing health policies are urgently needed...
  3. ncbi request reprint Important step forward in HIV-testing technologies [correction of technolgies]
    Kathryn A Phillips
    UCSF School of Pharmacy, Institute for Health Policy Studies, University of California San Francisco, 3333 California Street, Box 0613, San Francisco, CA 94143, USA
    Am J Prev Med 25:167. 2003
  4. ncbi request reprint Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey
    Kathryn A Phillips
    sSchool of Pharmacy and Institute of Health Policy Studies, University of California San Francisco, 3333 California Street, Suite 420, Box 0613, San Francisco, CA 94143, USA
    Am J Prev Med 24:340-8. 2003
    ..The objective of this study was to examine willingness to use instant home HIV tests and what test characteristics are most important to individuals...
  5. ncbi request reprint An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California Street 420 Box 0613, San Francisco, CA 94143, USA
    Pharmacogenomics 4:231-9. 2003
    ..We discuss the steps in conducting a cost-effectiveness or cost-benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature...
  6. ncbi request reprint New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women
    Kathryn A Phillips
    University of California at San Francisco, San Francisco, California 94143, USA
    J Acquir Immune Defic Syndr 32:182-91. 2003
    ..testing and patients accept counseling and testing, obtain their test results, seek treatment, and change risky behaviors? 4) Will the guidelines be relatively cost-effective? 5) Will the guidelines be compatible with ethical standards?..
  7. ncbi request reprint Prescription drug dispensing limits and patterns
    Kathryn A Phillips
    Health Economics and Health Services Research, School of Pharmacy, Institute for Health Policy Studies, University of California, San Francisco 94143, USA
    Manag Care Interface 18:41-6. 2005
    ..Prescription dispensing patterns may have important influences on adherence, therapeutic and preventive health outcomes, and costs. This study examined dispensing patterns for five drug classes commonly prescribed for chronic conditions...
  8. ncbi request reprint Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs
    Kathryn A Phillips
    Program in Pharmacogenomics and Population Screening, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
    Am J Manag Care 10:425-32. 2004
    ..To determine the potential impact of genetic testing and pharmacogenomics on healthcare delivery and costs...
  9. ncbi request reprint Health and economic benefits of increased beta-blocker use following myocardial infarction
    K A Phillips
    School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA
    JAMA 284:2748-54. 2000
    ..Understanding the consequences of underuse of beta-blockers is important because of the implications for current policy debates over quality-of-care measures and Medicare prescription drug coverage...
  10. ncbi request reprint Impact of the U.S. panel on cost-effectiveness in health and medicine
    Kathryn A Phillips
    School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, CA 94143, USA
    Am J Prev Med 22:98-105. 2002
    ..To examine whether recommendations made by the U.S. Panel on Cost-Effectiveness in Health and Medicine (Panel Report) have been associated with changes in how cost-effectiveness analyses are conducted...
  11. ncbi request reprint Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review
    K A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA
    JAMA 286:2270-9. 2001
    ....
  12. ncbi request reprint Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States)
    David A Haggstrom
    San Francisco General Hospital, Division of General Internal Medicine, University of California, San Francisco
    Cancer Causes Control 15:883-92. 2004
    ..To assess whether the specialty of a patient's primary care physician or being part of a gatekeeper plan influence breast and cervical cancer screening...
  13. pmc Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography
    Sherilyn Tye
    School of Pharmacy, University of California, San Francisco 94143, USA
    Health Serv Res 39:179-206. 2004
    ..To develop a framework of factors to characterize health plans, to identify how plan characteristics were measured in a national survey, and to apply our findings to an analysis of the predictors of screening mammography...
  14. ncbi request reprint Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings
    Aimee Afable-Munsuz
    University of California, San Francisco and Advancing New Standards in Reproductive Health ANSIRH program, Bixby Center for Reproductive Health Research and Policy, San Francisco, CA 94143, USA
    Contraception 75:45-51. 2007
    ..This study provides descriptive data on the diverse MAB practice models currently being utilized by US health care providers and the costs associated with the components of those models...
  15. pmc Are gatekeeper requirements associated with cancer screening utilization?
    Kathryn A Phillips
    School of Pharmacy, Institute of Health Policy Studies, UCSF Comprehensive Cancer Center, University of California, San Francisco 94143, USA
    Health Serv Res 39:153-78. 2004
    ..Our objective was to examine whether gatekeeper requirements are associated with the utilization of cancer screening for breast, cervical, and prostate cancer...
  16. ncbi request reprint Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services
    Su Ying Liang
    University of California, 3333 California St, Suite 420, Box 0613, San Francisco, CA 94143, USA
    Am J Manag Care 10:99-107. 2004
    ....
  17. ncbi request reprint Trends in colonoscopy for colorectal cancer screening
    Kathryn A Phillips
    University of California, San Francisco, CA 94143, USA
    Med Care 45:160-7. 2007
    ..A major health priority is to increase colorectal cancer screening, and colonoscopy has become an increasingly important method of screening. The Medicare program began coverage for colonoscopy for average risk individuals in 2001...
  18. ncbi request reprint Is the prevalence of gatekeeping in a community associated with individual trust in medical care?
    Jennifer S Haas
    Institute for Health Policy Studies, University of California, San Francisco, USA
    Med Care 41:660-8. 2003
    ..Consumer concerns about the restrictions of managed care may lead to distrust...
  19. pmc Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California San Francisco, 94143, USA
    Health Serv Res 37:1681-705. 2002
    ..To examine preferences for HIV test methods using conjoint analysis, a method used to measure economic preferences (utilities)...
  20. pmc Genomic testing and therapies for breast cancer in clinical practice
    Jennifer S Haas
    Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA University of California, San Francisco, San Francisco, CA Memorial Sloan Kettering Cancer Center, New York, NY and Aetna, Hartford, CT
    J Oncol Pract 7:e1s-7s. 2011
    ....
  21. pmc Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients
    Kathryn A Phillips
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
    Cancer 115:5166-74. 2009
    ..Human epidermal growth factor receptor 2 (HER2) testing to target trastuzumab for patients with breast cancer provides insights into the evidence needed for emerging testing technologies...
  22. pmc Rates and predictors of colorectal cancer screening
    Su Ying Liang
    School of Pharmacy, University of California, San Francisco, 3333 California St, Suite 420, Box 0613, San Francisco, CA 94143, USA
    Prev Chronic Dis 3:A117. 2006
    ....
  23. doi request reprint User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives
    Su Ying Liang
    UCSF Center for Translational and Policy Research in Personalized Medicine TRANSPERS Center, Department of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA
    Contraception 86:666-72. 2012
    ....
  24. doi request reprint Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling
    Grace Wang
    Center for Translational and Policy Research on Personalized Medicine TRANSPERS, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, USA
    Genet Med 13:1045-50. 2011
    ..We compared these policies with policies for breast cancer screening with magnetic resonance imaging to consider whether payers apply a unique policy approach to genetic services...
  25. ncbi request reprint Measuring managed care and its environment using national surveys: a review and assessment
    Su Ying Liang
    University of California, San Francisco, USA
    Med Care Res Rev 63:9S-36S. 2006
    ....
  26. doi request reprint Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006
    Su Ying Liang
    Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research in Personalized Medicine TRANSPERS Center, University of California San Francisco, San Francisco, CA 94143, USA
    Contraception 83:528-36. 2011
    ..Little is known about the out-of-pocket expenditures and dispensing patterns for oral contraceptive pills (OCPs), factors associated with these outcomes and whether they change over time...
  27. ncbi request reprint Patient costs for medication abortion: results from a study of five clinical practices
    Stephanie L Van Bebber
    Advancing New Standards in Reproductive Health program, Center for Reproductive Health Research and Policy, San Francisco, California, USA
    Womens Health Issues 16:4-13. 2006
    ..Our objective was to determine total patient costs for medication abortion. This information may be useful for improving counseling and patient decision making...
  28. ncbi request reprint Willingness to recommend a health plan: who is dissatisfied and what don't they like?
    Julie A Sakowski
    Department of Psychiatry, University of California San Francisco, Calif, USA
    Am J Manag Care 10:393-400. 2004
    ....
  29. ncbi request reprint Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States
    Jennifer S Haas
    Institute for Health Policy Studies, Division of General Internal Medicine, San Francisco General Hospital, CA, USA
    Med Care 40:743-51. 2002
    ..Despite the broad implementation of managed care, there is little information that specifically addresses how this type of coverage may affect ethnic disparities...
  30. pmc Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value
    Kathryn A Phillips
    University of California at San Francisco, Department of Clinical Pharmacy, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, San Francisco, CA 94143 USA
    Curr Opin Mol Ther 10:260-6. 2008
    ..Major challenges include a lack of linked data, the need for relevant research frameworks and methodologies, and the clinical complexities of genomic-based diagnostics and treatment...
  31. ncbi request reprint A qualitative study of insurers' coverage for mifepristone-induced abortion
    Marcel P Gemperli
    SCF, San Francisco, California 94143 1744, USA
    Manag Care Interface 18:26-30, 32. 2005
    ..A model coverage policy that contains comprehensive clinical information regarding appropriate clinical regimens for mifepristone is provided as an example for insurers and others in the field...
  32. ncbi request reprint Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
    Heart Rhythm 2:1294-300. 2005
    ..Genetic testing for long QT syndrome (LQTS) has been available in a research setting for the past decade, and a commercial test has recently become available. However, the costs and effectiveness of genetic testing have not been estimated...
  33. ncbi request reprint Out-of-pocket expenditures for oral contraceptives and number of packs per purchase
    Kathryn A Phillips
    School of Pharmacy and the Institute for Health Policy Studies, University of California, San Francisco, USA
    J Am Med Womens Assoc 59:36-42. 2004
    ..This study used nationally representative data to examine the out-of-pocket costs of OCPs and whether women obtain more than 1 pack per purchase...
  34. ncbi request reprint Colorectal cancer screening differential costs for younger versus older Americans
    Uri Ladabaum
    Division of Gastroenterology, University of California San Francisco, 94143 0538, USA
    Am J Prev Med 30:378-84. 2006
    ..It was therefore hypothesized that increased use of CRC screening and polypectomy in younger persons might yield CRC-related savings later in life for payers such as Medicare...
  35. pmc A review of studies examining stated preferences for cancer screening
    Kathryn A Phillips
    University of California, San Francisco, San Francisco, CA 94143 0613, USA
    Prev Chronic Dis 3:A75. 2006
    ..Our objectives were to conduct a systematic review of stated preference studies for cancer screening, identify gaps in the literature, and determine which types of research should be conducted in the future...
  36. pmc Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer
    Su Ying Liang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143, USA
    Med Care 49:e1-8. 2011
    ..Administrative claims and medical records are important data sources to examine healthcare utilization and outcomes. Little is known about identifying personalized medicine technologies in these sources...
  37. ncbi request reprint The intersection of biotechnology and pharmacogenomics: health policy implications
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and Comprehensive Cancer Center at the University of California, San Francisco, USA
    Health Aff (Millwood) 25:1271-80. 2006
    ..Key policy challenges include determining the appropriate role of policy in (1) providing incentives to develop socially beneficial interventions and (2) facilitating development of the evidence base...
  38. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
    ..Potential implications of this conclusion and future directions for research are discussed...
  39. ncbi request reprint Measuring the value of pharmacogenomics
    Kathryn A Phillips
    School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California Street, Box 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 4:500-9. 2005
    ..This review provides a framework for analysing the value of pharmacogenomic interventions, and suggests where further research and development could be most beneficial...
  40. ncbi request reprint Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration
    Kathryn A Phillips
    University of California, San Francisco, CA 94143, USA
    Med Care Res Rev 63:301-26. 2006
    ..This review identifies issues faced by the FDA with respect to PGx, which the FDA is addressing through several initiatives. It also illustrates the complex issues involved in developing, implementing, and adopting new technologies...
  41. ncbi request reprint Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006
    ..Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it...
  42. pmc The economic value of personalized medicine tests: what we know and what we need to know
    Kathryn A Phillips
    1 Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA 2 UCSF Philip R Lee Institute for Health Policy, San Francisco, California, USA 3 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA 4 UCSF Institute for Human Genetics, Center for Business Models in Healthcare, Chicago, Illinois, USA
    Genet Med 16:251-7. 2014
    ..There is uncertainty about when personalized medicine tests provide economic value. We assessed evidence on the economic value of personalized medicine tests and gaps in the evidence base...
  43. pmc Health technology assessment and private payers' coverage of personalized medicine
    Julia R Trosman
    Center for Translational and Policy Research in Personalized Medicine and Philip R Lee Institute for Health Policy Studies, University of California, San Francisco Center for Business Models in Healthcare, San Francisco, CA
    J Oncol Pract 7:18s-24s. 2011
    ..We examine the current use of HTA by private payers in coverage decisions for personalized medicine, a field that is increasingly impacting oncology practice...
  44. pmc Measuring what people value: a comparison of "attitude" and "preference" surveys
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California San Francisco, 94143, USA
    Health Serv Res 37:1659-79. 2002
    ..We explore possible explanations for our findings using focus groups conducted after the quantitative survey...
  45. ncbi request reprint Measuring patient preferences for colorectal cancer screening using a choice-format survey
    Deborah A Marshall
    McMaster University, Hamilton, ON, Canada
    Value Health 10:415-30. 2007
    ..Our objective is to examine patient preferences for CRC screening modalities and uptake rates using utility-based methods...
  46. pmc Angiotensin receptor blockers on the formularies of Medicare drug plans
    Walid F Gellad
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120 1613, USA
    J Gen Intern Med 22:1172-5. 2007
    ..The presence of angiotensin receptor blockers (ARBs) on the formularies of Medicare Part D prescription drug plans (PDPs) is vitally important to the health of seniors who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors...
  47. pmc How the new medicare drug benefit could affect vulnerable populations
    Walid F Gellad
    Department of Medicine, Brigham and Women s Hospital, in Boston, MA, USA
    Health Aff (Millwood) 25:248-55. 2006
    ....
  48. ncbi request reprint Biotechnology and Medicare's new technology policy: lessons from three case studies
    Patricia Seliger Keenan
    Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
    Health Aff (Millwood) 25:1260-9. 2006
    ..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments...
  49. ncbi request reprint An experiment on simplifying conjoint analysis designs for measuring preferences
    Tara Maddala
    Clinimetrics Research Inc, San Jose, California, USA
    Health Econ 12:1035-47. 2003
    ..However, evidence suggested that there were differences in stated preferences. The results increase our understanding of how respondents answer CA questions and how to improve future surveys...
  50. pmc Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening
    Jennifer S Haas
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120 1613, USA
    Prev Chronic Dis 4:A90. 2007
    ..However, another possible influence, the effect of regional differences in physicians' beliefs and recommendations on screening use, has not been assessed...
  51. pmc The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents
    Jennifer S Haas
    Division of General Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Public Health 93:2105-10. 2003
    ..We examined the effect of race, socioeconomic status, and health insurance status on the prevalence of overweight among children and adolescents...
  52. pmc The effect of area HMO market share on cancer screening
    Laurence C Baker
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
    Health Serv Res 39:1751-72. 2004
    ..We examine the relationship between area managed care activity and screening for breast, cervical, and prostate cancer among patients enrolled in more managed care plans and patients who are enrolled in less managed plans...
  53. ncbi request reprint Viagra and contraceptives
    Kathryn A Phillips
    Health Aff (Millwood) 22:277. 2003
  54. ncbi request reprint Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
    Curr Drug Saf 2:177-85. 2007
    ..A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts...
  55. ncbi request reprint Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
    ..Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution...
  56. ncbi request reprint Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence
    Jennifer S Haas
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusett 02160, USA
    Med Care 42:707-14. 2004
    ....